Ciloa focuses on the manufacturing of entirely natural membrane proteins on exosomes. Situated in Montpellier, France, the organization was established in 2011 by Robert MAMOUN and Bernadette TRENTIN. It emerged as a result of the CNRS and the University of Montpellier. The company possesses exclusive and patented technology for creating recombinant exosomes in the field of therapeutic and preventive applications. Ciloa's exosomes provide an innovative approach for producing a new class of therapeutic and preventive vaccines, monoclonal antibodies, immunotherapies, and therapeutic carriers delivering medication. Its unparalleled technology enables the targeting of previously inaccessible drug targets.